Ligand Pharmaceuticals (LGND) Non-Current Deffered Revenue (2010 - 2024)

Ligand Pharmaceuticals (LGND) has 12 years of Non-Current Deffered Revenue data on file, last reported at $2.2 million in Q4 2024.

• For the quarter ending Q4 2024, Non-Current Deffered Revenue rose 55.54% year-over-year to $2.2 million; the trailing twelve-month figure through Dec 2024 stood at $2.2 million (up 55.54% YoY), and the FY2024 full-year result was $2.2 million, up 55.54% from the prior year.
• Non-Current Deffered Revenue eased to $2.2 million in Q4 2024, from $2.5 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $9.3 million in Q4 2021 to a low of $44000.0 in Q4 2022.
• A 4-year average of $3.8 million and a median of $2.7 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue plunged 99.53% in 2022 and soared 3181.82% in 2023, its largest moves.
• Tracing LGND's Non-Current Deffered Revenue over 4 years: stood at $9.3 million in 2021, then sank by 99.53% to $44000.0 in 2022, then soared by 3181.82% to $1.4 million in 2023, then soared by 55.54% to $2.2 million in 2024.
• Business Quant data shows LGND's Non-Current Deffered Revenue at $2.2 million in Q4 2024, $2.5 million in Q3 2024, and $2.7 million in Q2 2024.